Emyria Limited, a clinical drug development and care delivery company, operates a network of specialist medical clinics.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.23|
|52 Week High||AU$0.069|
|52 Week Low||AU$0.27|
|1 Month Change||-4.26%|
|3 Month Change||18.42%|
|1 Year Change||192.21%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||55.17%|
Recent News & Updates
We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Emyria ( ASX:EMD...
|EMD||AU Healthcare||AU Market|
Return vs Industry: EMD exceeded the Australian Healthcare industry which returned 11.5% over the past year.
Return vs Market: EMD exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: EMD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: EMD's weekly volatility (9%) has been stable over the past year.
About the Company
Emyria Limited, a clinical drug development and care delivery company, operates a network of specialist medical clinics. Its product pipeline include EMD-003, a cannabinoid medicine for treating patients with mental health; and EMD-004, a cannabinoid medicine targeting irritable bowel syndrome. The company also provides a data platform that manages, monitors, and improves the safety and efficacy of novel treatments for patients with unmet medical needs.
Emyria Fundamentals Summary
|EMD fundamental statistics|
Is EMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EMD income statement (TTM)|
|Cost of Revenue||AU$2.26m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.019|
|Net Profit Margin||-248.30%|
How did EMD perform over the long term?See historical performance and comparison
Is Emyria undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EMD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EMD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EMD is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: EMD is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EMD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EMD is overvalued based on its PB Ratio (8x) compared to the AU Healthcare industry average (2.1x).
How is Emyria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Emyria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Emyria performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: EMD is currently unprofitable.
Growing Profit Margin: EMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EMD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare EMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: EMD has a negative Return on Equity (-68.35%), as it is currently unprofitable.
How is Emyria's financial position?
Financial Position Analysis
Short Term Liabilities: EMD's short term assets (A$6.9M) exceed its short term liabilities (A$1.0M).
Long Term Liabilities: EMD's short term assets (A$6.9M) exceed its long term liabilities (A$849.1K).
Debt to Equity History and Analysis
Debt Level: EMD is debt free.
Reducing Debt: EMD had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EMD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EMD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 36.8% each year.
What is Emyria current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EMD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Michael Winlo serves as Managing Director of Emyria Limited (formerly known as Emerald Clinics Limited) since November 26, 2019 and served as its Chief Executive Officer until November 26, 2019. Dr. Wi...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD349.25K) is about average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Experienced Management: EMD's management team is considered experienced (2.6 years average tenure).
Experienced Board: EMD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.
Emyria Limited's employee growth, exchange listings and data sources
- Name: Emyria Limited
- Ticker: EMD
- Exchange: ASX
- Founded: 2018
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: AU$55.900m
- Shares outstanding: 254.09m
- Website: https://www.emyria.com
- Emyria Limited
- D2, 661 Newcastle Street
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:03|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.